Stock listing

NASDAQ:REGN Regeneron Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Regeneron Pharmaceuticals, Inc.

Follow Regeneron Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:REGN

$790.74 USD -5.60 (-0.7%)

Delayed at least 15 minutes · 8:34 AM EDT, Oct 19, 2026

Past year +37.1% · daily closes, Oct 20, 2025 – Oct 16, 2026, adjusted for splits
Day range so far
$788.00 – $790.74 USDDelayed at least 15 minutes · 8:34 AM EDT, Oct 19, 2026
Volume
2,579 sharesDelayed at least 15 minutes · 8:34 AM EDT, Oct 19, 2026
Market value
$79.97B USDDelayed at least 15 minutes · 8:34 AM EDT, Oct 19, 2026 · price × 101.1M shares outstanding
52-week range
$572.75 – $859.34 USDLowest and highest trades, Oct 20, 2025 – Oct 19, 2026
Regeneron Pharmaceuticals, Inc. logo
Ticker
NASDAQ:REGN
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Upcoming

  • Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Call

    Fri, Oct 30, 2026 · 8:30 AM ET

    Register

Replays

  • Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 8:30 AM ET

    Watch Transcript

  • Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 8:30 AM ET

    Watch Transcript

  • Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2025 Earnings Call

    Fri, Jan 30, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Oct 16, 2026

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Oct 6, 2026

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Oct 1, 2026

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

Oct 1, 2026

Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency

Oct 1, 2026

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Oct 1, 2026

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

Sep 24, 2026

Students Earn Top Awards at CEE’s 43rd Annual Research Science Institute at MIT

Aug 26, 2026

Veeva Vault CRM Selected by Regeneron

Aug 25, 2026

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Aug 19, 2026

All Regeneron Pharmaceuticals, Inc. news

Decks

Regeneron Pharmaceuticals, Inc. on 6ix

News releases
75 in the last 12 months · 371 in all · newest Oct 16, 2026 · oldest 2020
Calls
31 calls with a replay · 31 with a transcript · latest Jul 30, 2026
Decks
62 decks · latest July 2026

Where Regeneron Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:REGN · Home listing · This pageNASDAQUnited StatesUSD
gettex:RGOgettexGermanyEUR
LS Exchange:881535LS ExchangeGermanyEUR
Tradegate:RGOTradegateGermanyEUR
BMV:REGNBMVMexicoMXN
B3:REGN34B3BrazilBRL
BOATS:REGNBOATSUnited StatesUSD
Frankfurt:RGOFrankfurtGermanyEUR
LSE:0R2MLSEUnited KingdomUSD
Lang & Schwarz:881535Lang & SchwarzGermanyEUR
Dusseldorf:RGODusseldorfGermanyEUR
VIE:REGNViennaAustriaEUR
BIVA:REGNBIVAMexicoMXN
Stuttgart:RGOStuttgartGermanyEUR
Milan:1REGNMilanItalyEUR
Munich:RGOMunichGermanyEUR
Turquoise:REGNNTurquoiseUnited KingdomUSD
Xetra:RGOXetraGermanyEUR
EUROTLX:4REGNEUROTLXItalyEUR
BX Swiss:RGOBX SwissSwitzerlandCHF
Hanover:RGOHanoverGermanyEUR
BVL:REGNUSBVLPeruPEN
Hamburg:RGOHamburgGermanyEUR

Log in to ask 6ix AI your own questions about Regeneron Pharmaceuticals, Inc.